

**Metabolic Endocrine Education Foundation
18372 Clark Street # 212 Tarzana, CA 91356**

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659


Register online: www.WCIR.org/CMEdinner
Please choose CME Dinner Symposium from the Menu

CME Symposium
IN ASSOCIATION WITH THE
FREE LIVE IN-PERSON ONLINE

20th
hybrid
WCIRDC

EARN
CME
ABIM-MOC
CREDITS
1.75

CKD and Heart Failure —the New Epidemic



Thursday December 1, 2022
7:30pm - 9:15pm PST
Hilton Universal City Hotel
Los Angeles, California
DINNER WILL BE SERVED

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**
Free for all 20th WCIRDC Attendees | Register Online: wcir.org/registration
This CME Symposium will be available and FREE for ONE year following the meeting.

Provided By:



Administered By:





CKD and Heart Failure —the New Epidemic

CHAIRS: Ralph DeFronzo, MD • Yehuda Handelsman, MD

- 7:30pm -7:45pm Introduction & Pre CME Questions
Yehuda Handelsman, MD
- 7:45pm – 7:55pm Epidemiology of HF & CKD in the General Population
Ralph DeFronzo, MD
- 7:55 pm – 8:10pm Guideline Directed Management of Heart Failure
Biykem Bozkurt, MD, PhD
- 8:10 pm – 8:25pm State of the Art Management of CKD
Robert Toto, MD
- 8:25 pm - 8:40pm The Intersection of CKD and HF
Stephen Greene, MD
- 8:40 pm – 9:15pm Panel Discussion - CKD and HF the Chicken and the Egg **Yehuda Handelsman, MD**
Panel: Ralph DeFronzo, MD • Stephen Greene, MD • Robert Toto, MD
Biykem Bozkurt, MD, PhD
Moderator: Yehuda Handelsman, MD
- 9:15 pm Adjourn

Program Description

Recent cardiovascular outcome trials (CVOTs) have demonstrated prevention of HF, CKD and ASCVD in patients with and without diabetes, specifically sodium glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP1-RAs), nonsteroidal mineralocorticoid receptor agonists (MRAs.) Recently we observed that the SGLT2i is effective in the prevention and management of the spectrum of HF from HF_{rEF} through HF_{pEF} Likewise, evidence supporting SGLT2 inhibition in patients with CKD and just like in HF in patients with and without diabetes.

The program will be held in conjunction with the 20th annual WCIRDC and will address gaps in physicians' knowledge of the epidemiology and interconnections between CKD and heart failure and management approaches when both are present in the same patient.

Learning Objectives

Upon completion of this symposium, participants should be able to:

- Discuss the epidemiology of HF and CKD
- Describe the evidence supporting treatment recommendations for HF and CKD
- Compare and contrast the benefits and limitations of established and emerging treatments for both HF and CKD based on outcome trial evidence
- Develop management strategies for patients with complicated disease, including those with CKD and heart failure

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

FACULTY



Yehuda Handelsman, MD
FACP, FNLA, MACE, Chair
Chair & Program Director, WCIRDC
Medical Director & Principal Investigator,
Metabolic Institute of America
Chair & Founder,
International Committee for Insulin Resistance
Chair & Founder, International Lipid Forum
Tarzana, California



Biykem Bozkurt, MD, PhD
FHFA, FACC, FAHA
Mary and Gordon Cain Chair and Professor of
Medicine Associate Provost of Faculty Affairs Senior
Associate Dean of Faculty Development Senior
Associate Editor for Circulation AHA/ASA Journals
Editor-in-Chief of Journal of the
American College of Cardiology
Baylor College of Medicine
Houston, Texas



Ralph A. DeFronzo, MD, Chair
Professor of Medicine Chief
Diabetes Division
University of Texas Health
Science Center at San Antonio
San Antonio, Texas



Stephen Greene, MD, FACC
Assistant Professor, Division of Cardiology
Advanced Heart Failure & Transplantation
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina



Robert D. Toto, MD
Professor of Internal Medicine
Associate Dean Translational Science and Education
University of Texas Southwestern Medical Center
Dallas, Texas

CME Supported Symposium is FREE

This CME Symposium will be available and FREE for ONE year following the meeting.

Learn more: WCIR.ORG/CMESymposium

This CME Supported Symposium is included with the
20th WCIRDC Live Interactive Online Registration

To register for the entire 20th WCIRDC FREE

Please visit wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or 818.342.1889

This is a CME Program Supported by an Educational Grant from **AstraZeneca**